Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
October 2025
The cell and gene therapy infrastructure market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.
The cell and gene therapy infrastructure market is growing because of increasing government approval, increasing demand for advanced therapies, and increasing awareness among people of genetic diseases, which increases the demand for cell and gene therapy infrastructure. North America dominated as growing government support in healthcare solutions, while the Asia Pacific is the fastest growing, with increasing partnerships with contract research organizations and advancements in technology.
The cell and gene therapy infrastructure market is expanding as this infrastructure has massive potential to offer innovative treatments for complex health conditions, and rapid advancements in gene-editing technology. Cell and gene therapies significantly improve patient outcomes and reduce the ongoing burden on the healthcare system. More than 6,000 diseases could be significantly treated by cell and gene therapies, affecting more than 350 million people globally. Cell and gene therapy (CGT) infrastructure refers to the whole multifaceted network of services, services, tools, and technology required to research, manufacture, develop, and deliver these modern therapies.
AI-driven technologies enable the advancement of a new therapy through the R&D value chain in different stages, including payload design optimization, target identification, translational and clinical development, and end-to-end (E2E) digitization. AI-driven technology in gene therapy efficacy and safety prediction by participating in different datasets. It constructs predictive models to assess treatment results.
AI and analytics are altering CGT production by lowering challenges, streamlining workflows, and making life-changing therapies accessible. This includes leveraging AI-driven algorithms to analyse genetic data and predict drug responses, eventually leading to more efficient and tailored treatment approaches. AI-driven technology delivers substantially greater efficacies in cell and gene therapy manufacturing and allows more patients to benefit from significant treatments, which contributes to the growth of the cell and gene therapy infrastructure market.
Increasing biotech approval to high-performance biomanufacturing, such as cell and gene therapies, contributes to the growth of the market.
For instance,
Increasing multi-state initiatives to enhance access to cell and gene therapies, which drive the growth of the market.
For Instance,
| Company | Approval |
| Integra Therapeutics | The company successfully closed a €10.7 million pre-Series A funding round in September 2025 to develop its gene writing platform for CAR-T therapies. |
| Akadeum Life Sciences | Closed a $20 million+ financing round in June 2025, led by Michigan Capital Network, to advance its cell separation technology. |
| Isomorphic Labs | The AI drug discovery company, which partners with major pharmaceutical firms, secured $600 million in financing in April 2025. |
In therapy type, the gene-modified cell therapy segment led the cell and gene therapy infrastructure market, as this type of used to treat, prevent, or manage certain inherited disorders, like cystic fibrosis, alpha-1 antitrypsin deficiency, hemophilia, beta thalassemia, and sickle cell disease. They also used to treat cancers or infections, including HIV. Genetic engineering of stem cells can be effective for cumulative cell survival when transplanted, specifically into an aggressive environment. They modified to deliver proteins to neighbouring cells, reduce graft-host rejection, or kill cancer cells.
On the other hand, the gene therapy segment is projected to experience the fastest CAGR in the cell and gene therapy infrastructure market from 2025 to 2034, as it provides a novel hope for people with genetic health conditions. It has the power to target the root cause of a disease. Gene therapy has massive potential to remove and prevent genetic diseases, like cystic fibrosis, and is a possible cure for heart disease, cancer, and AIDS. For gene therapy to be recognised as a permanent cure for any disorder, it has to be confirmed that the therapeutic DNA introduced into the target cells experiences expression for long and the cells expressing the therapeutic DNA are long-lived and stable.
By infrastructure component, the manufacturing facilities segment led the cell and gene therapy infrastructure market in 2024, as manufacturing facilities such as academic medicine serve to advance the scientific field and offer the highest quality of medical care. Hospital-driven Good Manufacturing Practice (GMP) facilities, which support mainly investigator-initiated clinical trials, are progressively involved in integration with industry. Cell and gene therapy clinical development impacts downstream progress to commercialization and patient access.
On the other hand, the supply chain & logistics segment is projected to experience the fastest CAGR in the cell and gene therapy infrastructure market from 2025 to 2034, as cell and gene therapies use rapid manufacturing processes to enhance production and delivery efficacy and avoid spoilage. It widely extends product shelf life as compared to refrigerated storage. Increase effectiveness by orchestrating the cell or gene therapy supply chain. In a limited time supply chain diminutions warehousing needs diminish, spoilage concerns, inventory valuation, and increase the flow of therapies and resulting in more effective, lean manufacturing techniques.
By delivery model, the centralized manufacturing & delivery segment led the cell and gene therapy infrastructure market in 2024, as centralized manufacturing benefits from a recognized supply chain. Centralized manufacturing allows businesses to take advantage of economies of scale. Combining production in a single facility often leads to inferior production expenses per unit. Bulk buying of raw materials, efficient production processes, and effective utilization of resources result in price savings.
On the other hand, the hybrid models segment is projected to experience the fastest CAGR from 2025 to 2034, as this drug delivery model creates an opportunity for novel technologies in a wide range of applications. The significant advantages of hybridization are to eliminate biological obstacles in the delivery of medicines. The design of hybrid gene delivery agents encompassing both virally derived and synthetic materials shows a promising strategy for the development of safe and efficient gene therapy vectors.
By end-user, the biotech & pharmaceutical companies segment led the cell and gene therapy infrastructure market in 2024, as cell and gene therapy infrastructure provides many advantages to the major healthcare companies, such as lower cost, quick supply of manufactured products in response to medical demand, and optimal organization and transport of cellular material. These therapies precisely eliminate or even replace a targeted gene by application of vectors to deliver novel genetic material. It provides convenience to cell collection services and manufacturing capabilities.
On the other hand, the contract development and manufacturing organizations (CDMOs) segment is projected to experience the fastest CAGR from 2025 to 2034, as CDMO efficiently manages labor, operations, materials, and quality of manufacturing cell and gene therapy, resulting in well cost control for drug manufacturers. Outsourcing CGT production to CDMOs enables companies to save expenses by removing the requirement to build in-house infrastructure. CDMO digital alteration is reshaping how cell and gene therapies (CGT) are produced. These therapies have emerged with ground-breaking potential and unprecedented difficulty.
North America is dominant in the cell and gene therapy infrastructure market in 2024, due to an increasing robust public and private investment, strong regulatory support and government frameworks, and an impenetrable ecosystem of biotech firms and research institutions. Rising government support, such as organizations like the National Institutes of Health (NIH), awards major grants to speed up research into gene-editing technologies and various CGT applications, which contributes to the growth of the market.
For Instance,
In the U.S. significant spending, scientific innovations, and supportive government initiatives. Recent innovations in gene-editing tools such as CRISPR, next-generation viral vectors, and non-viral delivery systems, which drive the growth of the market.
In April 2025, Global pharmaceutical company Novartis announced a $23 billion investment plan over the next five years to build and expand its healthcare infrastructure in the U.S. The move aims to ensure that all key Novartis medicines for U.S. patients are manufactured domestically.
Canada has strong government support and a robust research ecosystem for advanced healthcare manufacturing. This country is developing as a significant player, with its commercialization infrastructure, specifically in healthcare manufacturing, which drives the growth of the market.
In March 2025, OmniaBio’s expanded facility in Hamilton seeks to drive a 5X increase in manufacturing efficiency while reducing production and supply costs by up to 50%, facilitating patient access to life-saving treatments for chronic diseases, including cancer.
Asia Pacific is the fastest-growing region in the cell and gene therapy infrastructure market in the forecast period, due to the presence of a large aging population base, which increases the innovation ecosystem in healthcare. Major countries in the Asia Pacific, such as China, Japan, South Korea, and Singapore, have established dedicated funding to accelerate CGT development, driving the growth of the market. This expansion is with increased investments and specialized regulatory frameworks. For instance, South Korea created a $1.3 billion fund to help the sector, which contributes to the growth of the market.
For instance,
The research and development (R&D) process involves emerging robust and scalable manufacturing processes, confirming stringent quality control, and integrating advanced technologies to meet government requirements
Key Players: Novartis and CRISPR Therapeutics
The infrastructure for cell and gene therapy (CGT) clinical trials contributes complex, multi-stage methods that bridge preclinical research with human application. These trials need a highly specialized structure and a robust operational framework, from advancing the therapy in a lab to obtaining government approval
Key Players: Krystal Biotech and Intellia Therapeutics
The patient services processes in cell and gene therapy (CGT) infrastructure are extremely specialized and span the complete patient journey, from initial diagnosis to long-term follow-up.
Key Players: Atara Biotherapeutics and Bluebird Bio
By Therapy Type
By Infrastructure Component
By Delivery Model
By End User
By Region
October 2025
October 2025
October 2025
October 2025